Expertise in
6
conditions

Dr. Michael S. Simon

Oncology
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 
Accepting New Patients
Expertise in
6
conditions
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 

Overview

Michael Simon is an Oncologist practicing medicine in Detroit, Michigan.

Dr. Simon is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 9 clinical trials. Dr. Simon is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Karmanos Cancer Center
4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Study Phase: Phase 2
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women With Early Stage Breast Cancer
The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women With Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Other, Drug
Study Drug: Simvastatin
Study Phase: Phase 2
Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner
Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Other, Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

1 Total Publications

Common breast symptoms: when to refer to a breast surgeon.
Common breast symptoms: when to refer to a breast surgeon.
Journal: Advance for NPs & PAs
Published: November 28, 2013
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
313-576-8715
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elisabeth Heath is an Oncologist practicing medicine in Detroit, Michigan. Dr. Heath is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Heath is currently accepting new patients.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required
Before you request

Barbara Ann Karmanos Cancer Institute

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
Experience:
27+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Ammar Sukari is an Oncologist practicing medicine in Detroit, Michigan. He has been practicing medicine for over 27 years. Dr. Sukari is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Laryngeal Cancer, and Gastrostomy. Dr. Sukari is board certified in American Board Of Internal Medicine. Dr. Sukari is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
800-527-6266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anthony Shields is an Oncologist practicing medicine in Detroit, Michigan. Dr. Shields is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Squamous Cell Carcinoma of the Anal Canal (SCAC), Familial Colorectal Cancer, and Pancreatic Cancer. Dr. Shields is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
248-922-6650
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Ira Winer is an Oncologist practicing medicine in Detroit, Michigan. Dr. Winer is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginectomy, and Hernia Surgery. Dr. Winer is currently accepting new patients.

Expertise in
8
conditions
Dr. Michael U. Callaghan
Hematology | Oncology
Expertise in
8
conditions
Dr. Michael U. Callaghan
Hematology | Oncology
Referral may be required

DMC Children's Hospital Of Michigan

3901 Beaubien St, 
Detroit, MI 
 (0.1 miles away)
313-745-5515
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Callaghan is a Hematologist and an Oncologist practicing medicine in Detroit, Michigan. Dr. Callaghan is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Sickle Cell Disease, Evans Syndrome, and Splenectomy. Dr. Callaghan is currently accepting new patients.

Frequently Asked Questions about Dr. Michael S. Simon

How do I make an appointment with Dr. Michael S. Simon?

You can book an appointment with Dr. Michael S. Simon by calling their office at 313-576-8925. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael S. Simon a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael S. Simon is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael S. Simon specialize in?

While Dr. Michael S. Simon is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael S. Simon participate in research or clinical trials?

Yes. Dr. Michael S. Simon has published 1 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Michael S. Simon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael S. Simon accept my insurance?

Dr. Michael S. Simon accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 313-576-8925 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Simon's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile